Appointment dossier — Endometrial Carcinosarcoma
Bring this to your appointment. It summarizes what published studies report — it is not medical advice and does not say anything works. Decisions are yours and your care team’s.
Compounds studied in Endometrial Carcinosarcoma
- Carboplatin — Review evidence · 0 positive / 1 negative-mixed · PMID 36585027
- Paclitaxel — Review evidence · 0 positive / 1 negative-mixed · PMID 36585027
“Positive” means a study reported a positive result — most are early lab/animal work that may not translate to people.
Open recruiting trials (18)
- NCT03651206 · Phase 2 / Phase 3 — Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib (France)
- NCT05902988 · Phase 1 / Phase 2 — A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer (United States)
- NCT06638931 · Phase 2 — Agnostic Therapy in Rare Solid Tumors (Brazil)
- NCT05269381 · Phase 1 / Phase 2 — Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors (United States)
- NCT01174121 · Phase 2 — Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer (United States)
- NCT06943521 · Phase 1 / Phase 2 — A Study of MT-4561 in Patients With Various Advanced Solid Tumors (United States)
- NCT06333314 · Phase 2 — Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI (France)
- NCT07070518 · Phase 1 / Phase 2 — Study of GV20-0251 in Participants With Solid Tumor Malignancies (China)
- NCT05238922 · Phase 1 — Study of INCB123667 in Subjects With Advanced Solid Tumors (United States)
- NCT06840886 · Phase 1 — A Study of PHST001 in Advanced Solid Tumors (United States)
- NCT07458347 · Phase 1 — A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation (United States)
- NCT06771219 · Phase 1 — SLV-154 Treatment of Metastatic Solid Tumors (United States)
- NCT06349642 — Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform (United States)
- NCT07327489 — Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (United States)
- NCT03422198 · Phase 3 — Short Course Vaginal Cuff Brachytherapy in Treating Participants With Stage I-II Endometrial Cancer (United States)
- NCT05256225 · Phase 3 — Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma (United States)
- NCT05646316 · Phase 3 — Impact of Sentinel Lymph Node Mapping on Patient Reported Lower Extremity Limb Dysfunction in Stage I Endometrial Cancer (United States)
- NCT05559879 · Phase 1 / Phase 2 — Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma (United States)
Most-relevant first: trials that name Endometrial Carcinosarcoma, then broader trials you may still qualify for. Eligibility is decided by each trial's team — bring these NCT numbers to your appointment.
Questions to ask your oncologist
- Of the open trials I found (for example NCT03651206), am I eligible for any — here or at a larger cancer center?
- What is my exact diagnosis — the type, subtype, stage, and grade?
- Has my tumor had molecular or genomic testing (e.g. next-generation sequencing), and what did it find?
- Should I have inherited (germline) genetic testing, and could it affect my treatment or my family?
- What is the goal of treatment for me — cure, long-term control, or comfort?
- What are all of my standard treatment options, and what does each one involve?
- What is the realistic benefit of each option, in actual numbers?
- What are the most common and the most serious side effects, and how are they managed?
- How will we know if treatment is working, and how often will I be scanned or tested?
- If the first treatment doesn't work, what are the next options?
- Are there gentler options if I want to prioritize quality of life?
- Am I eligible for any clinical trials — here or at a larger/academic cancer center?
- Is my case reviewed by a multidisciplinary tumor board?
- Would a second opinion at a center that treats my cancer often be worthwhile?
- Could any of my prescriptions, over-the-counter drugs, or supplements interfere with treatment?
- Which symptoms are emergencies, and who do I call after hours?
- Should I see palliative or supportive care alongside my treatment?
- How will treatment affect my daily life, work, and (if it matters to me) fertility?
- What can I safely do myself — diet and activity — and is anything I'm taking risky?
- What will treatment cost, and is financial assistance available?
- Should my tumor tissue be stored (biobanked) for future testing or trials?